

### **Remarks**

Amendments were made to the specification to correct typographical and spelling errors, with two exceptions:

- On page 34, two patents were listed having the first inventor named incorrectly (Bell and Schaffner should have been Cousens and Koszinowski, respectively).
- A cross reference was added to the first page, immediately following the title line.

Amendments were made to the claim set, canceling original Claims 1-33, and adding new Claims 34-47. Basis for the new claims can be found in at least the following locations in the specification as originally filed:

New claim #	Location for original basis
34	Original Claim 11 and Figures 4 and 5
35	Original Claim 17
36	Original Claim 1
37	Original Claim 2
38	Original Claim 3
39	Original Claim 4
40	Original Claim 25
41	Original Claim 17; Page 7, lines 14-21
42	Original Claim 1; Page 7, lines 14-21
43	Original Claim 2; Page 7, lines 14-21
44	Original Claim 3; Page 7, lines 14-21
45	Original Claim 4; Page 7, lines 14-21
46	Page 37, line 3
47	Page 37, line 17

None of the amendments submitted herein constitute new matter to the application. The Applicants respectfully request that these amendments be fully entered by the Examiner, and that the application be advanced to allowance.

Preliminary Amendment for Application No. PCT/US2004/015786 (Publ. No. WO 2004/103404)  
X-16760A Watkins, Jeffry Dean, et al.  
CD20 Binding Molecules

Respectfully submitted,

*Paula K. Davis*

Paula K. Davis  
Attorney for Applicants  
Registration No. 47,517  
Phone: 317-433-3422

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 19, 2005